Introduction
============

Androgens exert a significant influence on the structure, function and/or pathophysiology of many ocular tissues, including the meibomian gland, lacrimal gland, conjunctiva, and cornea \[[@r1]-[@r12]\]. These hormones regulate such ocular parameters as glandular architecture, protein synthesis and secretion, meibum production, mucus expression, aqueous tear output, tear film stability, immune activity, and epithelial cell dynamics \[[@r1]-[@r12]\]. Androgens have also been reported to correct defects, facilitate wound healing \[[@r6],[@r7],[@r13]\], suppress angiogenesis \[[@r14]\], and stimulate mitosis \[[@r9]\] in the corneal epithelium, to alter the development of allergic conjunctivitis \[[@r5]\], and to attenuate inflammation in autoimmune lacrimal tissue \[[@r8],[@r11]\]. In addition, androgens have been proposed as a topical therapy for the treatment of aqueous-deficient and evaporative dry eye diseases \[[@r8],[@r11]\]. However, despite these observations, the precise mechanisms underlying androgen-eye interactions in humans remain to be clarified.

We hypothesize that androgen action on the eye involves the local, intracrine synthesis of this sex steroid from adrenal precursors (e.g., dehydroepiandrosterone), binding to saturable, high-affinity and androgen-specific receptors, control of gene transcription, and ultimately modulation of translation. In support of this hypothesis, we have discovered that the human meibomian and lacrimal glands, and immortalized corneal and conjunctival epithelial cells, contain all the steroidogenic enzyme mRNAs necessary for the intracrine synthesis and metabolism of androgens \[[@r15]\]. Moreover, we have shown that androgen receptor mRNA and protein are present in epithelial cell nuclei of the human meibomian and lacrimal glands, cornea and conjunctiva \[[@r16],[@r17]\].

To continue to test our hypothesis, we examined the influence of androgens in gene expression in immortalized human meibomian gland and conjunctival epithelial cells.

Methods
=======

Cell culture and hormone treatment
----------------------------------

Immortalized human meibomian gland epithelial cells, which were recently generated in our laboratory \[[@r2]\], were cultured in Keratinocyte Serum-Free Medium \[KSFM\] supplemented with 50 μg/ml bovine pituitary extract (BPE), 5 ng/ml epidermal growth factor (EGF), and 100 U penicillin-streptomycin (Invitrogen, Carlsbad, CA). Cells were incubated in a humidified, 37 °C chamber under 5% CO~2~/95% air. Immortalized human conjunctival epithelial cells, which were gifted by Dr. Ilene Gipson (Boston, MA), were cultured in serum-free conditions as previously described \[[@r18]\].

When approximately 80% confluent, cells were exposed to 10 nM dihydrotestosterone (DHT; Steraloids, Wilton, NH) or placebo for 3 (meibomian) or 4 (conjunctiva) days. These time periods were previously shown to be optimal for the generation of DHT-induced alterations in androgen receptor mRNA levels in the different cell types \[[@r19]\]. For these studies the DHT was dissolved in ethanol and aliquots were evaporated in sterilized vials before the addition of medium. The placebo was prepared by transferring media to vials containing the residue of evaporated ethanol. After hormone treatment, cells were harvested and processed for RNA isolation.

Molecular biologic procedures
-----------------------------

Total RNA was extracted with RNAqueous Kits (Ambion, Austin, TX) and evaluated on a RNA Nano 6000 Series II Chip with a 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA) to confirm RNA integrity. The RNA concentrations and associated 260/280 nm ratios were determined using a NanoDrop 1000 Spectrophotometer (Thermo Scientific, Waltham MA).

The RNA (100 ng) samples were processed by Asuragen (Austin, TX) for the determination of mRNA levels by using Illumina HumanHT-12 v3 Expression BeadChips (San Diego, CA).These BeadChips target more than 25,000 annotated genes with over 48,000 probes derived from NCBI reference sequences and the UniGene databases. In brief, biotin-labeled cRNA samples were generated by using a MessageAmp™ II-based protocol (Ambion Inc., Austin, TX), quantitated by UV spectrophotometry and analyzed with an Agilent 2100 Bioanalyzer capillary electrophoresis system. The labeled cRNAs were used to probe the BeadChips. Hybridization, washing, and scanning of the Illumina arrays were conducted according to the manufacturer's instructions. Data were processed with Illumina BeadStudio software v3 by using both background subtraction and cubic spline normalization. Standardized hybridization intensity values were adjusted by adding a constant, so that the lowest intensity value for any sample equaled 16 \[[@r20]\].

Normalized data were analyzed with GeneSifter.Net software (Geospiza, Seattle, WA), a comprehensive program that also produced gene ontology and z-score reports. Ontologies included biologic processes, molecular functions and cellular components and were organized according to the guidelines of the Gene Ontology Consortium ([GO](http://www.geneontology.org/GO)) \[[@r21]\]. Gene expression data were analyzed with and without log transformation and statistical analyses of these data were performed with Student's *t*-test (two-tailed, unpaired). Genes that were up- or down-regulated in the same direction in different experiments were identified by using the GeneSifter.Net intersector program ([Geospiza](http://www.geospiza.com/)). All data from the Illumina BeadChips are accessible for download through the National Center for Biotechnology Information's Gene Expression Omnibus ([GEO](http://www.ncbi.nlm.nih.gov/geo)) via series accession numbers ([GSE18091](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE18091) and [GSE18094](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE18094)).

Real time PCR procedures
------------------------

The differential expression of selected genes was verified by using quantitative real-time PCR (qPCR) procedures. The cDNAs were transcribed by employing SuperScript III Reverse Transcriptase (Invitrogen, Grand Island, NY) and random hexamer primers (Invitrogen). The qPCR reactions were performed in triplicate by using TaqMan Gene Assays (Applied Biosystems, Inc., Foster City, CA) and TaqMan-specific primers and probes for aldo-keto reductase family 1, member c2 (Hs00413886_m1\*), cdc28 protein kinase regulatory subunit 2 (Hs01048812_g1\*), EGF-containing fibulin-like extracellular matrix protein 1 (Hs002444575_m1\*), interferon α-inducible proteins 6 (Hs00242571_m1\*), kallikrein related peptidase 11 (Hs01100849_m1\*), keratin 16 (Hs00373910_g1\*),

laminin, α3 (Hs00165042_m1\*), leupaxin (Hs00183105_m1\*), minichromosome maintenance component 3 (Hs00172459_m1\*), myosin light chain 6 (Hs00819642_m1; conjunctival epithelial cell endogenous control), n (α) acetyltransferase 50 (Hs00363889_m1\*; meibomian gland epithelial cell endogenous control), plasminogen activator, urokinase (Hs00170182_m1), serum amyloid A1 (Hs00761940_s1), and uridine phosphorylase 1 (Hs00427695_m1\*). Differential gene expression was calculated according to the Comparative Ct method, as outlined in Applied Biosystems User Bulletin 2 (updated 2001).

Results
=======

Androgen impact on gene expression in human ocular surface and meibomian gland epithelial cells
-----------------------------------------------------------------------------------------------

To determine the effect of DHT on gene expression in immortalized human meibomian gland and conjunctival epithelial cells, cells were exposed to placebo or DHT and processed for analysis by using Illumina BeadChips and [Geospiza](http://www.geospiza.com/) software.

Our results demonstrate that DHT had a significant impact on the expression of approximately 3,000 genes in immortalized human meibomian gland and conjunctival epithelial cells ([Table 1](#t1){ref-type="table"}). The relative direction of this hormone effect was about the same in both cell types, with DHT up- and down-regulating similar percentages of genes (i.e., meibomian: 49.8% ↑; conjunctiva: 44.8% ↑). Examples of genes that showed notable hormone-induced differences in terms of ratios are listed in [Table 2](#t2){ref-type="table"} and [Table 3](#t3){ref-type="table"}. In addition, DHT significantly enhanced the expression of genes encoding mucin 16 (2.2 fold ↑, conjunctiva) and reduced the activity of genes for S100 calcium binding proteins A8 and A9 (2.1 and 1.4 fold ↓, respectively, conjunctiva). Analysis of BeadChip raw data also revealed that DHT caused an 8.0 and 39.7 fold decrease in the mRNA levels of the small proline-rich proteins 2F and 2A, respectively, in meibomian gland epithelial cells.

###### Influence of DHT on gene expression in human meibomian gland and conjunctival epithelial cells.

  **Immortalized human epithelial cell type**   **DHT\>Placebo**   **Placebo\>DHT**   **Total**
  --------------------------------------------- ------------------ ------------------ -----------
  Meibomian gland                               1,485              1,494              2,979
  Conjunctiva                                   1,350              1,662              3,012

Gene expression was significantly (p\<0.05) upregulated in cells exposed to DHT or placebo treatment, as shown by the analysis of log-transformed data.

###### Effect of DHT on gene expression ratios in immortalized human meibomian gland epithelial cells.

  **Accession \#**   **Gene**                                                     **Ratio**   **p value**   **Ontology**
  ------------------ ------------------------------------------------------------ ----------- ------------- ---------------------------------------------------
  **DHT\>Placebo**                                                                                          
  NM_001001552       LEM domain containing 1                                      10.1        0.00000       nuclear envelope
  NM_032563          Late cornified envelope 3D                                   4.5         0.00024       keratinization
  NM_152565          ATPase, H^+^ transporting, lysosomal 38 kDa, V0 subunit d2   3.7         0.00048       ion transport
  NM_021244          Ras-related GTP binding D                                    3.5         0.00010       positive regulation of TOR signaling cascade
  NM_001031615       Aldehyde dehydrogenase 3 family, member B2                   3.0         0.00004       alcohol metabolic process
  NM_000435          Notch homolog 3                                              2.9         0.00015       regulation of transcription, DNA-dependent
  NM_005218          Defensin, β1                                                 2.6         0.00001       chemotaxis
  NM_001003679       Leptin receptor                                              2.5         0.00553       energy reserve metabolic process
  NM_001047          Steroid-5α-reductase, α polypeptide 1                        1.9         0.00097       androgen biosynthetic process
  NM_005063          Stearoyl-CoA desaturase                                      1.7         0.00039       fatty acid biosynthetic process
  NM_002015          Forkhead box O1                                              1.6         0.00006       blood vessel development
  **Placebo\>DHT**                                                                                          
  NM_181800          Ubiquitin-conjugating enzyme E2C                             24.4        0.00000       cell cycle checkpoint
  NM_001067          Topoisomerase (DNA) II α 170 kDa                             16.7        0.00000       resolution of meiotic recombination intermediates
  NM_018454          Nucleolar and spindle associated protein 1                   15.6        0.00006       mitotic sister chromatid segregation
  NM_001255          Cell division cycle 20 homolog                               13.4        0.00001       cell cycle checkpoint
  NM_001786          Cyclin-dependent kinase 1                                    12.3        0.00000       cell cycle checkpoint
  NM_001168          Baculoviral IAP repeat-containing 5                          10.2        0.00000       G2/M transition of mitotic cell cycle
  NM_004701          Cyclin B2                                                    9.5         0.00002       cell cycle checkpoint
  NM_002263          Kinesin family member C1                                     9.0         0.00000       mitotic sister chromatid segregation
  NM_002994          Chemokine (C-X-C motif) ligand 5                             8.9         0.00019       chemotaxis
  NM_003246          Thrombospondin 1                                             4.7         0.00001       activation of MAPK activity
  NM_002727          Serglycin                                                    2.5         0.00012       apoptosis
  NM_004994          Matrix metallopeptidase 9                                    1.7         0.00001       proteolysis

Relative ratios were calculated by comparing the degree of gene expression in meibomian gland epithelial cells treated with placebo or DHT. The mean gene intensity level in at least one group exceeded 100 BeadChip units.

###### Influence of DHT on gene expression ratios in immortalized human conjunctival epithelial cells.

  **Accession \#**     **Gene**                                          **Ratio**   **p value**   **Ontology**
  -------------------- ------------------------------------------------- ----------- ------------- ------------------------------------------------
  **DHT\>Placebo**                                                                                 
  NM_004994            Matrix metallopeptidase 9                         10.9        0.00000       proteolysis
  NM_001012964         Kallikrein-related peptidase 6                    10.5        0.00001       proteolysis
  NM_001323            Cystatin E/M                                      10.4        0.00002       epidermis development
  NM_003856            Interleukin 1 receptor-like 1                     9.0         0.00006       immune response
  NM_018043            Anoctamin 1, calcium activated chloride channel   8.0         0.00001       ion transport
  NM_002153            Hydroxysteroid (17β) dehydrogenase 2              7.8         0.00000       steroid biosynthetic process
  NM_005416            Small proline-rich protein 3                      7.4         0.00023       epidermis development
  NM_144947            Kallikrein-related peptidase 11                   7.2         0.00003       proteolysis
  NM_001077491         Kallikrein-related peptidase 5                    7.1         0.00018       proteolysis
  NM_198129            Laminin, α3                                       5.6         0.00001       epidermis development
  **Placebo \> DHT**                                                                               
  NM_002993            Chemokine (C-X-C motif) ligand 6                  12.4        0.00005       chemotaxis
  NM_003186            Transgelin                                        10.8        0.00013       muscle organ development
  NM_002974            Serpin peptidase inhibitor, clade B, member 4     10.1        0.00000       immune response
  NM_001733            Complement component 1, r subcomponent            9.4         0.00012       proteolysis
  NM_005602            Claudin 11                                        8.8         0.00005       cell adhesion
  NM_006820            Interferon-induced protein 44-like                8.5         0.00001       immune response
  NM_016352            Carboxypeptidase A4                               8.4         0.00033       proteolysis
  NM_003641            Interferon induced transmembrane protein 1        8.0         0.00001       cell surface receptor linked signaling pathway
  NM_001710            Complement factor B                               7.7         0.00000       proteolysis
  NM_001044391         Mucin 1, cell surface associated                  3.1         0.00127       protein binding

Relative ratios were determined by comparing the degree of gene expression in conjunctival epithelial cells treated with placebo or DHT. The mean gene intensity level in at least one group was higher than 100 BeadChip units.

Genes that demonstrated the greatest alterations in terms of statistical significance included those increased or decreased by DHT in immortalized human meibomian gland (aldo-keto reductase family 1, member C2 ↑, p\<0.000001; DNA topoisomerase IIα ↓, p\<0.000001), and conjunctival (uridine phosphorylase 1 ↑, p\<0.000001; interferon, α-inducible protein 6 ↓, p\<0.000001) epithelial cells.

The nature of androgen action on gene expression was predominantly cell-specific. Thus, 61.0 and 53.6% of upregulated genes, and 58.1 and 52.0% of downregulated genes, were unique to the meibomian gland and conjunctival epithelial cells, respectively. In addition, between 12.9 to 20.0% of regulated genes were expressed in the opposite direction in these immortalized cells ([Table 4](#t4){ref-type="table"}).

###### Opposite effects of DHT on gene expression in immortalized human meibomian gland and conjunctival epithelial cells.

  **Cell 1**   **Cell 2**    **C1 ↑, C2 ↓ (Genes)**   **%**        **C1 ↓, C2 ↑ (Genes)**   **%**
  ------------ ------------- ------------------------ ------------ ------------------------ ------------
  Meibomian    Conjunctiva   199                      12.9--14.2   255                      18.3--20.0

Log transformed data were analyzed and the total number of genes with [GEO](http://www.ncbi.nlm.nih.gov/geo) sequence identities in each category was then determined. Gene expression was significantly (p\<0.05) up (↑)- or down (↓)-regulated by DHT in the specific cell type. Abbreviations: "C" stands for "cell."

The genes regulated by DHT were located on a variety of chromosomes. As shown in [Table 5](#t5){ref-type="table"}, the cellular pattern of this regulation showed some similarities and dissimilarities.

###### Effect of DHT on chromosomal gene expression in immortalized human meibomian gland and conjunctival epithelial cells.

  **Chromosome**        **DHT Genes ↑**   **Plac Genes ↑**   **DHT z-score**   **Plac z-score**
  --------------------- ----------------- ------------------ ----------------- ------------------
  **Meibomian gland**                                                          
  16                    66                53                 **3.35**          1.34
  19                    80                62                 **2.61**          0.2
  18                    34                17                 **2.13**          −1.44
  2                     73                95                 **-2.23**         0.21
  17                    69                77                 1.52              **2.65**
  22                    25                35                 0.42              **2.59**
  8                     51                32                 −0.08             **-2.83**
  13                    23                14                 −1.23             **-2.93**
  **Conjunctiva**                                                              
  16                    66                45                 **4.08**          −0.49
  20                    51                37                 **3.84**          0.18
  1                     143               147                **3.51**          1.77
  19                    73                73                 **2.42**          0.94
  8                     32                40                 **-2.33**         **-2.22**
  13                    15                19                 **-2.39**         **-2.37**
  3                     47                94                 **-2.57**         1.77
  X                     24                46                 **-2.63**         −0.19
  4                     35                60                 **-2.72**         −0.51
  5                     34                82                 **-3.6**          1.27
  12                    46                92                 −1.53             **3.15**
  17                    51                85                 −0.31             **2.94**
  15                    34                26                 0.2               **-2.13**
  7                     64                44                 1.51              **-2.51**
  2                     88                75                 0.27              **-2.76**

Chromosomes with the highest and lowest z-scores were selected after analysis of log-transformed Illumina BeadChip data. A z-score is a statistical rating of the relative expression of genes, and shows how much they are over- or under-represented in a given gene list \[[@r59]\]. Positive z scores represent a greater number of genes meeting the criterion than is expected by chance, whereas negative z scores reflect fewer genes meeting the criterion than expected by chance \[[@r59]\]. Z-scores with values \>2.0 or \<-2.0 are quite significant and are highlighted in bold print. Terms: DHT Genes ↑ - number of genes upregulated in DHT-treated cells; Plac Genes ↑ - number of genes upregulated in placebo-treated cells; z-score - specific score for the upregulated genes in the DHT- and placebo-exposed cells.

To confirm in part the Illumina BeadChip results, selected genes were analyzed by qPCR. This experimental approach verified the alterations of all tested genes ([Table 6](#t6){ref-type="table"}).

###### Confirmation of selected Illumina BeadChip chip results by qPCR.

  **Gene**                                                     **Illumina ratio**   **qPCR ratio**
  ------------------------------------------------------------ -------------------- ----------------
  **Meibomian Gland Epithelial Cells**                                              
  **DHT\>Placebo**                                                                  
  Keratin 16                                                   2.4                  5.7
  Aldo-keto reductase family 1, member C2                      2.6                  1.7
  Kallikrein-related peptidase 11                              1.8                  2.4
  **Placebo\>DHT**                                                                  
  CDC28 protein kinase regulatory subunit 2                    3.1                  1.5
  Minichromosome maintenance component 3                       3.5                  19.3
  Leupaxin                                                     3.1                  57.8
  **Conjunctival Epithelial Cells**                                                 
  **DHT\>Placebo**                                                                  
  Laminin, α3                                                  5.6                  6.9
  Plasminogen activator, urokinase                             5.3                  1.1
  Uridine phosphorylase 1                                      4.2                  2.7
  **Placebo\>DHT**                                                                  
  Interferon, α-inducible protein 6                            4.8                  1.6
  Serum amyloid A1                                             5.7                  3.1
  EGF-containing fibulin-like extracellular matrix protein 1   4.9                  2.5

The expression of designated genes, that were shown to be significantly altered in DHT-treated cells by using Illumina BeadChips, were re-examined with qPCR procedures. The qPCR data from meibomian gland cells were standardized to N (α) acetyltransferase B complex 50 and data from conjunctival cells were normalized to myosin, light chain 6, alkali, smooth muscle and non-muscle. Neither of the genes used for standardization responded to DHT exposure. The relative ratios of gene expression in 3 separate experiments are listed in the Illumina and qPCR "Ratio" columns.

Androgen influence on the expression of gene ontologies and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways in human ocular surface and meibomian gland epithelial cells
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Androgen administration had a significant impact on the biologic process, molecular function and cellular component gene ontologies, as well as on the KEGG pathways, in human ocular surface and meibomian gland epithelial cells.

As shown in [Table 7](#t7){ref-type="table"}, DHT significantly increased numerous ontologies in immortalized human meibomian gland epithelial cells, such as those associated with protein metabolism, signaling, tissue development, oxidoreductase and peptidase activities, intracellular organelles and peroxisomes. Treatment with DHT also stimulated 25 different ontologies (with ≥5 genes) concerned with lipid biosynthesis, homeostasis, transport and binding, as well as with cholesterol, fatty acid, phospholipid and steroid dynamics, as we recently reported \[[@r2]\]. In turn, DHT decreased ontologies linked to cell cycle, M phase, DNA metabolic processes, angiogenesis, innate immunity, RNA binding, and ribonucleoprotein complexes. These effects of DHT were paralleled by significant alterations in KEGG pathways. Androgen exposure upregulated pathways related to insulin, mTOR and peroxisome proliferator-activated receptor (PPAR) signaling, and downregulated those involved with the cell cycle, RNA transport and cancer ([Table 8](#t8){ref-type="table"}).

###### Influence of DHT on the expression of gene ontologies in human meibomian gland epithelial cells.

  **Ontology**                                               **DHT Genes ↑**   **Plac Genes ↑**   **DHT z-score**   **Plac z-score**
  ---------------------------------------------------------- ----------------- ------------------ ----------------- ------------------
  **Biologic Process**                                                                                              
  programmed cell death                                      136               143                **5.18**          **5.09**
  oxidation-reduction process                                95                61                 **4.85**          −0.42
  protein metabolic process                                  280               278                **4.35**          **2.85**
  purine ribonucleotide metabolic process                    50                37                 **3.8**           0.87
  nerve growth factor receptor signaling pathway             28                22                 **3.38**          1.44
  response to hormone stimulus                               61                48                 **3.36**          0.7
  regulation of signaling                                    132               106                **3.14**          −0.45
  tissue development                                         80                69                 **2.58**          0.46
  cell cycle                                                 75                202                −0.65             **13.58**
  M phase                                                    14                107                **-3.29**         **13.34**
  DNA metabolic process                                      38                118                −0.87             **11.17**
  organelle fission                                          12                81                 **-2.41**         **11.94**
  RNA processing                                             39                111                −0.49             **10.47**
  angiogenesis                                               21                30                 1.05              **2.95**
  immune system process                                      99                122                0.86              **2.66**
  innate immune response                                     27                41                 −0.08             **2.28**
  blood vessel development                                   30                35                 1.49              **2.15**
  regulation of cellular biosynthetic process                139               148                **-2.24**         **-2.39**
  regulation of transcription                                111               119                **-2.26**         **-2.33**
  neurologic system process                                  59                33                 **-3.68**         **-7.15**
  **Molecular Function**                                                                                            
  protein binding                                            572               707                **6.41**          **13.12**
  hydrogen ion transmembrane transporter activity            21                3                  **5.82**          −1.58
  oxidoreductase activity, acting on CH-OH group of donors   23                9                  **5.47**          0.17
  catalytic activity                                         423               403                **5.11**          **2.27**
  translation factor activity, nucleic acid binding          16                8                  **4.47**          0.82
  peptidase activity                                         55                36                 **3.01**          −0.63
  RNA binding                                                61                127                1.12              **10.03**
  nucleotide binding                                         164               243                1.32              **7.58**
  ATPase activity                                            31                42                 1.61              **3.59**
  helicase activity                                          7                 20                 −0.89             **3.2**
  ion channel activity                                       14                12                 **-2.51**         **-3.15**
  DNA binding                                                115               149                **-2.82**         −0.43
  zinc ion binding                                           121               99                 −0.68             **-3.47**
  transporter activity                                       82                50                 0.41              **-3.94**
  transmembrane receptor activity                            33                26                 **-5.76**         **-6.98**
  **Cellular Component**                                                                                            
  vacuole                                                    56                20                 **7.82**          −0.56
  lysosome                                                   45                20                 **6.54**          0.19
  intracellular organelle                                    721               852                **5.76**          11.82
  organelle membrane                                         191               152                **5.26**          0.86
  endoplasmic reticulum                                      109               76                 **4.97**          0.28
  peroxisome                                                 19                4                  **4.85**          −1.23
  nuclear part                                               165               335                −0.05             **13.77**
  organelle lumen                                            195               344                1.62              **13.26**
  ribonucleoprotein complex                                  37                104                0.52              **12.01**
  chromosome                                                 27                97                 −1.62             **10.08**
  spindle                                                    9                 47                 −0.99             **9.87**
  extracellular space                                        37                57                 **-2.23**         0.31
  cell junction                                              38                28                 −0.19             −2.17
  extracellular region                                       98                105                **-3.36**         **-3.26**
  intrinsic to membrane                                      307               246                **-2.55**         −7.7

Designated ontologies were selected after the analyses of log-transformed data. Criteria for inclusion were an ontology containing ≥8 genes and having a z-score \>2.0 or \<-2.0. High and low values for the placebo (Plac) and DHT groups in specific ontologies are highlighted in bold print. Androgen administration also stimulated over 25 different ontologies related to lipid biosynthesis, homeostasis, transport and binding, as previously shown \[[@r2]\].

###### DHT impact on KEGG pathways in human meibomian gland epithelial cells.

  **KEGG Pathway**                            **DHT Genes ↑**   **Plac Genes ↑**   **DHT z-score**   **Plac z-score**
  ------------------------------------------- ----------------- ------------------ ----------------- ------------------
  Lysosome                                    26                7                  **5.76**          −1.06
  Oxidative phosphorylation                   21                8                  **4.3**           −0.57
  Peroxisome                                  16                3                  **4.24**          −1.48
  Aldosterone-regulated sodium reabsorption   9                 2                  **3.41**          −0.83
  Insulin signaling pathway                   21                9                  **3.35**          −0.82
  mTOR signaling pathway                      10                3                  **3.18**          −0.67
  PPAR signaling pathway                      12                3                  **3.01**          −1.24
  DNA replication                             1                 19                 −1.05             **9.94**
  Spliceosome                                 4                 39                 −1.93             **9.2**
  Cell cycle                                  5                 36                 −1.53             **8.41**
  Mismatch repair                             1                 11                 −0.51             **7.22**
  RNA transport                               12                27                 0.14              **4.27**
  p53 signaling pathway                       7                 15                 0.79              **4.03**
  Small cell lung cancer                      8                 17                 0.61              **3.89**

Pathways were selected after the analysis of log-transformed data. The criterion for inclusion was a pathway having a z-score \>2.0 or \<-2.0. High and low values for the placebo (Plac) and DHT groups in specific pathways are highlighted in bold print.

The influence of DHT on immortalized human conjunctival epithelial cells was quite different than that observed in human meibomian gland epithelial cells. As demonstrated in [Table 9](#t9){ref-type="table"}, DHT enhanced the expression of genes related to epithelium development, regeneration, wound healing, cell migration, Wnt receptor signaling, antioxidant activity and vacuoles, and reduced those associated with translation, RNA processing, mitotic cell cycle, immune response, JAK-STAT cascades, NADH dehydrogenase activity and ribosomes. In addition, androgen administration stimulated KEGG pathways linked to lysosomes, p53 signaling and endocytosis, and suppressed pathways involved with oxidative phosphorylation, the proteosome and RNA transport ([Table 10](#t10){ref-type="table"}).

###### Effect of DHT on the expression of gene ontologies in human conjunctival epithelial cells.

  **Ontology**                                     **DHT Genes ↑**   **Plac Genes ↑**   **DHT z-score**   **Plac z-score**
  ------------------------------------------------ ----------------- ------------------ ----------------- ------------------
  **Biologic Process**                                                                                    
  apoptosis                                        141               152                **6.33**          **4.91**
  response to stress                               215               252                **5.14**          **4.87**
  regulation of signal transduction                129               100                **5.02**          −0.55
  epithelium development                           50                33                 **4.95**          0.25
  nerve growth factor receptor signaling pathway   33                21                 **4.95**          0.74
  regeneration                                     18                9                  **4.87**          0.51
  wound healing                                    61                47                 **3.95**          0.1
  cell proliferation                               106               144                **3.17**          **5.15**
  cytokine production                              32                30                 **2.99**          1.36
  cell migration                                   53                41                 **2.61**          −0.81
  cell adhesion                                    69                58                 **2.46**          −0.79
  MAPKKK cascade                                   35                19                 **2.59**          −1.84
  canonical Wnt receptor signaling pathway         15                14                 **2.32**          1.18
  toll-like receptor 4 signaling pathway           10                10                 **2.06**          1.39
  translation                                      27                109                −0.12             **13.76**
  viral reproduction                               19                103                −1.64             **12.88**
  innate immune response                           33                68                 1.36              **6.69**
  RNA processing                                   26                93                 −2.41             **6.63**
  cell cycle checkpoint                            16                43                 0.43              **6.36**
  macromolecule metabolic process                  411               583                0.7               **5.9**
  gene expression                                  189               331                −2.00             **5.18**
  immune response                                  69                103                1.66              **4.27**
  mitotic cell cycle                               54                82                 1.65              **4.2**
  JAK-STAT cascade                                 5                 14                 0.27              **3.85**
  antigen processing and presentation              2                 12                 −0.98             **3.53**
  system process                                   69                64                 **-4.59**         **-7.03**
  neurologic system process                        57                40                 **-3.59**         **-7.13**
  regulation of transcription                      105               117                **-2.41**         **-3.68**
  **Molecular Function**                                                                                  
  protein binding                                  562               709                **6.93**          **9.48**
  enzyme inhibitor activity                        44                22                 **6.2**           −0.08
  SH3 domain binding                               21                9                  **5.25**          0.05
  cell adhesion molecule binding                   9                 4                  **3.85**          0.35
  antioxidant activity                             10                8                  **3.57**          1.89
  catalytic activity                               374               450                **2.59**          **2.73**
  translation initiation factor activity           7                 11                 **2.09**          **3.63**
  voltage-gated ion channel activity               3                 9                  **-2.8**          −1.65
  structural constituent of ribosome               5                 69                 −1.71             **16.86**
  RNA binding                                      32                153                **-2.89**         **12.32**
  threonine-type endopeptidase activity            0                 14                 −1.22             **9.88**
  NADH dehydrogenase activity                      0                 16                 −1.56             **8.37**
  small GTPase regulator activity                  22                8                  0.82              **-3.22**
  zinc ion binding                                 95                98                 **-2.84**         **-4.69**
  DNA binding                                      103               137                **-3.53**         **-2.83**
  G-protein coupled receptor activity              8                 13                 **-6.46**         **-6.7**
  **Cellular Component**                                                                                  
  vacuole                                          43                32                 **5.27**          1.48
  cytoplasm                                        642               854                **8.33**          **13.06**
  intracellular                                    792               1059               **5.01**          **11.05**
  cell surface                                     43                30                 **3.99**          0.03
  lysosome                                         34                32                 **4.2**           **2.45**
  intracellular organelle part                     389               592                **2.42**          **9.7**
  organelle                                        631               924                **2.15**          **11.22**
  intrinsic to membrane                            293               281                **-2.3**          **-7.61**
  ribonucleoprotein complex                        18                128                **-2.64**         **14.84**
  ribosome                                         6                 68                 −1.74             **14.78**
  mitochondrion                                    80                224                −0.25             **13.3**
  membrane part                                    361               366                −1.26             **-6.2**

Specific ontologies were selected after the analyses of log-transformed data. Criteria for inclusion in the Table were an ontology containing ≥8 genes and having a z-score \>2.0 or \<-2.0. High and low values for the placebo (Plac) and DHT groups in designated ontologies are highlighted in bold print.

###### DHT influence on KEGG pathways in human conjunctival epithelial cells.

  **KEGG Pathway**                         **DHT Genes ↑**   **Plac Genes ↑**   **DHT z-score**   **Plac z-score**
  ---------------------------------------- ----------------- ------------------ ----------------- ------------------
  Bacterial invasion of epithelial cells   16                5                  **5.02**          −0.81
  Lysosome                                 20                16                 **3.89**          1.15
  p53 signaling pathway                    13                8                  **3.69**          0.43
  Axon guidance                            18                3                  **2.89**          −2.97
  Endocytosis                              25                17                 **2.78**          −0.8
  Ribosome                                 1                 48                 −2.25             **13.98**
  Oxidative phosphorylation                7                 38                 −0.53             **8.25**
  Proteasome                               2                 20                 −0.73             **7.76**
  Antigen processing and presentation      2                 14                 −1.35             **3.04**
  RNA transport                            8                 24                 −0.98             **2.42**

Pathways were chosen after the analysis of log-transformed data. The criterion for inclusion was a z-score \>2.0 or \<-2.0. High and low values for the placebo (Plac) and DHT groups in designated pathways are highlighted in bold print.

Of interest, some ontologies were increased in both immortalized cell populations, regardless of treatment, such as cell death and apoptosis. In addition, there were ontologies that were decreased by androgens in both immortalized cells, including cellular component biogenesis, cellular location, innate immune response and nucleic acid metabolic processes. However, the majority of changes in gene ontologies and KEGG pathways appeared to be cell-specific.

Discussion
==========

The present study demonstrates that androgen treatment significantly influences the expression of thousands of genes in immortalized human meibomian gland and conjunctival epithelial cells. The nature of this DHT action is predominantly cell-specific: some androgen responses are shared by both cell types, the majority are unique, and others are completely opposite. Depending upon the cell type, DHT exerts a significant effect on many gene ontologies and KEGG pathways, including those related to lipid dynamics, innate immunity, cell cycle, JAK-stat cascades, oxidative phosphorylation, the proteasome, and mTOR, Wnt and PPAR signaling. Our findings support our hypothesis that androgens regulate gene expression in human meibomian gland and conjunctival epithelial cells.

Our finding that the nature of DHT action on ocular surface and adnexal cells is predominantly cell-specific is not surprising. It is well established that androgen effects are not necessarily the same in different tissues. For example, androgens increase immunoglobulin A (IgA) and secretory component (SC) expression in the lacrimal gland, appear to have no influence on IgA or SC levels in salivary, respiratory, intestinal, uterine or bladder tissues, and actually decrease IgA amounts in the mammary gland \[[@r22],[@r23]\]. In addition, we have found that testosterone induces a 7.8- to 13-fold increase in epidermal growth factor and nerve growth factor mRNA levels in the submandibular gland \[[@r24]\] but has no effect on these factors in the lacrimal gland (unpublished). Conversely, testosterone stimulates the expression of submandibular androgen-repressed protein (SMARP) in the lacrimal gland, but suppresses SMARP levels in the submandibular gland \[[@r25]\]. As another example, androgens promote the angiogenic activity of prostate epithelial cells, but reduce such activity by prostate stromal cells \[[@r26]\]. In effect, the nature of androgen influence is generally cell- and tissue-specific.

Androgen exposure caused a striking impact on gene expression in immortalized human meibomian gland epithelial cells. Most notable were the effects of DHT on lipid- and keratin-related genes. Androgen treatment induced a significant increase in the activity of numerous genes associated with lipogenesis and cholesterogenesis \[[@r2]\]. This hormone response is analogous to the androgen influence on meibomian glands in vivo \[[@r27]-[@r30]\], wherein testosterone stimulates many genes linked to lipid metabolic pathways. Androgen administration also led to a 40 fold decrease in the mRNA level of small proline-rich protein 2A (SPPR2A). This gene, which is significantly upregulated in human meibomian gland dysfunction (MGD) \[[@r31]\], encodes a protein that promotes keratinization \[[@r32]\]; keratinization, in turn, is believed to be a primary cause of MGD and the consequent tear film hyperosmolarity and evaporative dry eye \[[@r3]\]. The SPPR2A gene is also significantly downregulated by androgens in meibomian glands of male and female mice \[[@r27],[@r28]\]. These combined DHT effects, increasing lipogenesis and suppressing keratinization, may begin to explain how topical androgens enhance the synthesis and secretion of meibomian gland lipids, prolong the tear film breakup time and alleviate evaporative dry eye disease \[[@r32],[@r33]\]. In addition, these DHT effects may account for why androgen insufficiency (e.g., during anti-androgen treatment, complete androgen insensitivity syndrome and/or aging) is associated with keratinization of the meibomian gland ductal epithelium (i.e., orifice metaplasia), altered meibum lipid profiles, and a reduced quality of meibomian gland secretions \[[@r34]-[@r38]\].

Androgen treatment also led to a significant change in the expression of many other genes in immortalized human meibomian gland epithelial cells, such as those associated with steroidogenesis, microbial protection, tissue development, oxidative stress, mTOR and PPAR signaling, cell cycle, innate immunity and angiogenesis. Androgen administration upregulated the mRNA levels of defensin β1, an antimicrobial peptide implicated in epithelial surface resistance to microbial colonization \[[@r39]\], as well as steroid-5α-reductase, α polypeptide 1, which catalyzes the conversion of testosterone into the more potent androgen, DHT \[[@r39]\]. This steroid regulation appears to be a form of feed-forward control exerted by DHT on its own biosynthesis \[[@r40]\]. Androgen increased the gene expression of leptin receptor, involved in the regulation of fat metabolism, glucose homeostasis, wound healing and the immune system \[[@r39]\]; FOXO1, a transcription factor that mediates cell responses to oxidative stress \[[@r39]\] and is known to interact with androgen receptors \[[@r41]\]; and stearoyl-CoA desaturase, an iron-containing enzyme that catalyzes the synthesis of unsaturated fatty acids. Testosterone enhances stearoyl-CoA desaturase mRNA levels in mouse male and female meibomian glands \[[@r27],[@r28]\], and the targeted disruption of this rate-limiting enzyme causes meibomian gland atrophy \[[@r42]\]. Androgen exposure also increased ontologies and pathways related to peroxisomes, which are organelles involved in metabolism of fatty acids and other metabolites \[[@r39]\]; PPAR, which may promote tissue differentiation \[[@r43],[@r44]\]; and mTOR, a serine/threonine protein kinase that may modulate cell growth, cell proliferation, cell motility, cell survival, protein synthesis and transcription \[[@r39],[@r45],[@r46]\], and is also activated by androgens in the prostate \[[@r47]\]. Androgen administration downregulated genes related to cell cycle regulation (e.g., ubiquitin-conjugating enzyme E2C, cyclin-dependent kinase 1 and cyclin B2), innate immunity (e.g., chemokine (C-X-C motif) ligand 5 and thrombospondin 1) \[[@r39],[@r48]\] and angiogenesis (e.g., thrombospondin 1). Thrombospondin 1 mRNA content is also decreased by androgens in the prostate, bladder and breast cancer cells \[[@r49]-[@r52]\]. Also notable was the DHT suppression of gene expression for matrix metallopeptidase 9, an enzyme that is increased in the tear film in dry eye and is known to promote corneal inflammation \[[@r53]\].

The effect of DHT on immortalized human conjunctival epithelial cells was quite different than that observed in human meibomian gland epithelial cells. For example, androgen administration enhanced the expression of genes involved in epithelium development, regeneration, wound healing and cell migration (e.g., matrix metallopeptidase, kallikrein-related peptidases 5, 6 & 11, cystatin E/M, laminin, α3), and suppressed those related to the immune response (e.g., chemokine (C-X-C motif) ligand 6, serpin peptidase inhibitor, clade B, member 4, complement component 1, r subcomponent, interferon-induced protein 44-like, interferon induced transmembrane protein, complement factor B) and mitotic cell cycle (e.g., septin 4, endothelin 1, F-box protein 6 and proteasome subunit, β type, 9). The decrease in immune-related gene activity may play a role in the reported androgen ability to alter the development of allergic conjunctivitis \[[@r5]\] and to attenuate the immune effect of lipopolysaccharide in both conjunctival and meibomian gland epithelial cells \[[@r54]\]. The downregulation of conjunctival genes associated with the cell cycle, which was also found in immortalized human meibomian gland epithelial cells, may reflect a hormone-induced bias toward cell differentiation as compared to proliferation. Androgens are also known to inhibit the cell cycle in other tissues \[[@r55]-[@r57]\].

Of particular interest was the DHT upregulation of mucin 16 (MUC16), and downregulation of mucin 1 (MUC1), gene expression in the conjunctival epithelial cells. These transmembrane mucins help to prevent pathogen penetrance into the eye and to maintain a wet ocular surface phenotype \[[@r18]\]. The mucin gene intensities in our study were relatively low, especially for MUC16. This finding may reflect the fact that we cultured cells in serum-free media: exposure of conjunctival epithelial cells to serum, which leads to their stratification, has been reported to promote mucin expression \[[@r18]\]. It is possible that the lack of serum may also have influenced the nature of the MUC1 response to DHT. Thus, others have shown that androgen increases MUC1 expression when breast and prostate cell lines are cultured in serum \[[@r58]\]. This observation would be consistent with the decreased MUC1 levels found in the conjunctiva an individual with complete androgen insensitivity syndrome \[[@r12]\]. We are currently investigating whether the presence or absence of serum causes significant variations in the molecular biologic response of ocular surface and adnexal cells to androgen administration.

Ultimately, it is very important to demonstrate that cellular responses in vitro duplicate those in vivo. Such demonstrations, as we have recently done with androgens and the meibomian gland \[[@r2],[@r27]-[@r31],[@r34]-[@r38]\], may provide new and meaningful insight into the regulation of ocular surface cells in health and disease.
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